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Background: Therapeutic options for patients with Multiple
myeloma (MM) whose disease has relapsed after a prior
autologous stem cell transplant (SCT) include an expanding
armamentarium of novel agents, often combined with
traditional chemotherapy, or a second SCT, with no clear
standard of care.
Methods: We retrospectively analyzed the outcomes of pa-
tients who underwent salvage melphalan-based SCT for
relapsed MM at Memorial Sloan-Kettering Cancer Center.
Results: Between 1995 and 2012, 75 patients with MM
received an initial SCTand then second autograft for relapsed
disease at our center. Conditioning was with melphalan
200mg/m2 (N¼43), 180mg/m2 (N¼1), 140mg/m2 (N¼22),
100mg/m2 (N¼9). The median age at 2nd SCT was 59 years
(range 36-75) and 58% (N¼35) were male. Of those with
available data, 35% had high risk cytogenetics (including t
(4;14), +1q, p53 loss or del 13q by karyotype) at the time of
second SCT. Median interval between ﬁrst and salvage SCT
was 38 months (range 7 -113). Of 71 evaluable patients, 73%
had chemotherapy sensitive disease prior to salvage SCT and
27% were chemoresistant. Response was assessed at 2-3 mos
post-SCT and 84% of evaluable patients achieved >¼ partial
response (PR),10% had stable disease (SD), and 7% progressed
despite salvage SCT. Following salvage SCT, 37 patients
received maintenance therapy and 15 went on to allogeneic
SCT. The median PFS following second autograft was 10.1
mos (95% CI: 7.9-13.6); the median OS was 24 mos (95% CI:
19.5e 50.5). Patients with chemosensitive relapse had better
progression free survival (HR-0.51, CI: 0.22-0.77, P ¼ .005)
and overall survival (HR¼0.37, CI- 0.19-0.70, P ¼ .002) than
patients with resistant relapse. Those with high-risk cyto-
genetics at the time of second SCT had higher risk of death
(HR 2.12, 95% CI: 1.03- 4.38, P ¼ .04) compared to patients
with standard risk cytogenetics.
Conclusions: Salvage SCT is an effective strategy for relapsed
MM with chemosensitive disease and results in comparablePFS and OS to other salvage strategies. With the FDA approval
of multiple novel effective therapies, more relapsed patients
will likely achieve measurable responses and should be
evaluated for second stem cell transplant. Incorporation of
novel conditioning regimens and/or effective maintenance
strategies may further improve outcomes with this approach125
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Introduction: There are few s studies about cytomegalovirus
reactivation after autologous peripheral blood stem cell
transplantation (PBSCT).
Methods: At our center we retrospectively reviewed the ﬁles
for all adult patients with diagnosis of lymphoma or multiple
myeloma (MM), who underwent autologous PBSCT between
2007-2012.
All these patients were on acyclovir or valacyclovir pro-
phylaxis, CMV pp65 antigenemia testing was performed
weekly till day 40 post transplant, and preemptive therapy
was started if the antigenemia test was positive in 5 cells, or
more than once positive<5 cells plus unexplained low
counts, or elevated liver enzymes.
Results: During the six years period, 210 patients underwent
autologous transplant (lymphoma 55%, MM45%).97.6% of the
patients were CMV IgG positive before transplant.
The rate of CMV reactivation requiring preemptive ther-
apy as per the criteria above was 17.6%, with median time for
reactivation of 31 days.
There was no difference in the rate of reactivation be-
tween lymphoma and MM, and lymphoma.
Ganciclovir was used as ﬁrst line therapy in 70.3%, Val-
ganciclovir in 24.3% and Foscarnet in 5.4%. The median
duration of induction therapy was 8 days and for mainte-
nance was 10 days.
None of our patients developed CMV disease in any organ,
and the main toxicity was cytopenia with the Ganciclovir/
Vaganciclovir, and renal impairment with electrolytes
imbalance with Foscarnet.
At the time of the study 76% of the group were alive, with
55% were free of progression.
Conclusion: CMV reactivation rate is low after autologous
PBSCT, no need for CMV monitoring beyond 40 days, and
with preemptive therapy you can eradicate CMV infection.126
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